Table of contents


On 19 November 2007, orphan designation (EU/3/07/494) was granted by the European Commission to Celgene Europe Limited, UK, for lenalidomide for the treatment of chronic lymphocytic leukaemia.

The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in July 2018.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2019 on request of the Sponsor.

Key facts

Active substance
Disease / condition
Treatment of chronic lymphocytic leukaemia
Date of first decision
EU designation number

Sponsor's contact details

Celgene Europe B.V.
Winthontlaan 6 N
3526 KV Utrecht
Tel. +31 (0)30 284 4547

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating